Sep 11, 2023
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer

Sep 05, 2023
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 23, 2023
AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements

Aug 15, 2023
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update

Aug 09, 2023
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast

Aug 08, 2023
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Jul 18, 2023
AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates

Jul 10, 2023
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Jul 05, 2023
AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series

Jun 27, 2023
AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research

 1   2   3   4     5    6   7   8   9   10